<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500461</url>
  </required_header>
  <id_info>
    <org_study_id>AC2106213</org_study_id>
    <nct_id>NCT00500461</nct_id>
  </id_info>
  <brief_title>Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705</brief_title>
  <official_title>A Single-centre, Open-label, Sequential Ascending Cross Over Study to Examine Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Ascending Single Doses, Nominally 10, 30, 70 and 110µg Intravenous Doses and a Single 250µg Oral Dose of GSK233705 in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK233705 is being developed for the treatment of chronic obstructive pulmonary disease. This
      will be an open-label, dose-ascending study in 7 healthy male subjects to establish well
      tolerated intravenous doses and an oral dose of GSK233705. The main objective of the study is
      to confirm an IV and oral dose for a definitive human radiolabel metabolic study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2007</start_date>
  <completion_date type="Actual">July 25, 2007</completion_date>
  <primary_completion_date type="Actual">July 1, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of GSK233705: lead II monitoring out to 8 hours post dose,</measure>
    <time_frame>out to 8 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of heart rate, blood pressure and ECG, Holter monitoring and laboratory data out to 24 hours and</measure>
    <time_frame>out to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>review of adverse events ongoing through out study.</measure>
    <time_frame>through out study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentrations of GSK233705 and derived pharmacokinetic parameters, out to 48 hours post dose.</measure>
    <time_frame>out to 48 hours post dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects receiving GSK233705</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive one or more ascending doses given as a constant rate IV infusion over 30 minutes and a single oral dose of 250 microgram GSK233705 solution. IV doses will include 30, 70, 110 microgram of GSK233705 at specified time points.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK233705</intervention_name>
    <description>GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.</description>
    <arm_group_label>Subjects receiving GSK233705</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects;

          -  Between the ages of 18-55 years, inclusive

          -  Body mass index within the range 18.0 to 30.0 kg/m2.

          -  Non-smokers

          -  Adequate venous access for intermittent cannulation

          -  A signed and dated written informed consent is obtained from the subject

          -  The subject is capable of giving informed consent

          -  Available to complete the study

        Exclusion Criteria:

          -  Any clinically important abnormality identified in the following: at the screening
             medical assessment

          -  A mean QTc(B) value at screening &gt;450msec, the QTc(B) of the 3 screening ECGs are not
             within 10% of the mean, a PR interval outside the range 90-210msec or an ECG that is
             not suitable for QT measurements

          -  A history of elevated resting blood pressure or a mean blood pressure higher than
             140/90 mmHg at screening.

          -  A mean heart rate outside the range of 40-90 bpm at screening.

          -  History of use of tobacco- or nicotine-containing products within 6 months of
             screening or a positive cotinine test at screening.

          -  The subject has donated a unit (400ml) of blood within 60 days of screening, or,
             intends to donate during the study.

          -  The subject is currently taking regular (or course of) medication, whether prescribed
             or not, including herbal remedies such as St John's Wort.

          -  The subject has taken: prescription medications within the past 2 weeks prior to
             dosing, or OTC medications (except simple analgesics) within 48 hours prior to dosing,
             unless it is judged by the Investigator not to compromise their safety or influence
             the outcome of the study.

          -  The subject has participated in a study with a new molecular entity within a period of
             3 months prior to dosing.

          -  The subject has tested positive for hepatitis C antibody, hepatitis B surface antigen
             or HIV
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/AC2106213?search=study&amp;search_terms=AC2106213#rs</url>
    <description>Results for study AC2106213 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>This study has not been published in the scientific literature.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscarinic Receptor Antagonist,</keyword>
  <keyword>intravenous infusion,</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy subjects,</keyword>
  <keyword>safety,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>Anticholinergic,</keyword>
  <keyword>oral dosing,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>AC2106213</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2106213</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2106213</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2106213</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2106213</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2106213</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2106213</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

